Replimune soars on melanoma data, aims for oncolytic virus launch next year

2024-06-06
Firstwordpharma
临床研究临床结果
Shares of Replimune jumped 28% Thursday after the company shared that its oncolytic virus RP1, in combination with Opdivo (nivolumab), achieved a one-third overall response rate (ORR) in patients with melanoma who failed prior anti-PD-1 treatment.
The company now plans to submit an application with the FDA next half for RP1, and begin enrolling the confirmatory IGNYTE-3 study in the third quarter. CEO Sushil Patel added that Replimune expects to commercially launch the therapy next year.
Topline results from the Phase I/II IGNYTE-3 study demonstrate that, in 140 evaluable patients, RP1 plus Bristol Myers Squibb’s PD-1 inhibitorPD-1 inhibitor led to a median duration of response exceeding 35 months, with all responses lasting more than 6 months.
Replimune said that the primary analysis by independent central review was triggered once all patients had been followed for at least 12 months.
RP1 is a genetically modified strain of herpes simplex virus engineered with fusogenic protein GALV-GP R- and GM-CSF to boost potency, immunogenicity, and the activation of a systemic anti-tumor immune response.
The company plans to present the primary analysis data, including key secondary endpoint data and subgroups, at an upcoming medical congress.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
机构
适应症
靶点
药物
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。